The Wegovy pill topped 100,000 prescriptions within its first two months on the U.S. market, a steeper early climb than injectable Wegovy or Zepbound showed at their launches, according to a study in the Annals of Internal Medicine reported by Healio. Researchers analyzed national prescription data from July 2020 through June 2026.
Prescriptions for injectable semaglutide and injectable tirzepatide kept rising after the pill arrived. The researchers concluded the pill mainly added new users rather than pulling patients away from shots.